Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
SPN-817 by Supernus Pharmaceuticals for Epilepsy: Likelihood of Approval
SPN-817 is under clinical development by Supernus Pharmaceuticals and currently in Phase II for Epilepsy. According to GlobalData, Phase II...